Short communication · 4 Aug 2026
Conference abstractPublished 14 Apr 2014
Safety and tolerability of regadenoson in patients with chronic obstructive pulmonary disease or asthma
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Regadenoson is a selective adenosine A2a receptor agonist, now being used extensively for radionuclide myocardial perfusion imaging (MPI). Patients with reactive airway disease are at an increased risk for adenosine induced bronchoconstriction via stimulation of A2b and A3 receptors. Methods: All patients who underwent radionuclide MPI using regadenoson stress test over a period of one year at our institution were included in this study. Patient demographics, past medical history including medications, hemodynamic data and the development of symptoms during the test were collected. The use of aminophylline to counter the effects of regadenoson in symptomatic patients was also recorded. Patients with chronic obstructive pulmonary disease (COPD) or asthma were compared to patients without COPD/asthma (control) using the above variables. Results: The study included 799 patients with a mean age of 61±13 years. Out of the total cohort, 151(19%) had COPD/ asthma with a mean age of 59±12 years and 32% were men. Patients with COPD/asthma had a higher incidence of shortness of breath (29.8% vs. 18.2%; p=0.0015) and headache (16.5% vs. 8.9%; p=0.0058) when compared to the control group. However, no patients developed active wheezing during the test. Symptoms of chest discomfort, dizziness, gastrointestinal discomfort, nausea or arrhythmias were not significantly different between the groups. The use of aminophylline was significantly higher among COPD/asthma patients as compared to the control group (26.4% vs. 19.1%, p=0.043). Changes in systolic blood pressure, diastolic blood pressure and heart rate response to regadenoson bolus were similar between the groups. There were no hemodynamically significant arrhythmias or serious adverse events in either group. Conclusions: Patients with COPD/asthma undergoing regadenoson MPI had a higher incidence of shortness of breath and headache resulting in an increased use of aminophylline. Regadenoson was hemodynamically well tolerated without any serious adverse events in COPD/asthma patients
Subjects
CardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical and Experimental Cardiology.
Conference abstract · 15 Jun 2026
Speckle Tracking Echocardiography for Early Identification of Chemotherapy-Induced Cardiotoxicity
Conference abstract · 15 Jun 2026
Coronary CT Angiography as a First-Line Diagnostic Tool for Stable Chest Pain: Clinical Outcomes from a Multicenter Study
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical and Experimental Cardiology
- SubjectCardiology
- BylineArticles whose byline prints “Mahek Shah”
- BylineArticles whose byline prints “Kamal Joshi”
- BylineArticles whose byline prints “Marvin Lu”
- BylineArticles whose byline prints “Adnan Khan”
- BylineArticles whose byline prints “Aman Amanullah”
